Valve-in-valve procedure for bioprosthesis dysfunction in rheumatic patients: a new procedure for an old disease

Abstract Background Bioprosthetic heart valve has a limited durability and lower long-term performance especially in rheumatic patients. The standard treatment for degenerated bioprosthesis involves redo open-heart surgery, which is associated with significant morbidity mortality, particularly high-risk Minimally invasive procedures, as valve-in-valve (ViV) implantation, may offer an attractive therapy alternative. Methods aim of this study was to evaluate the characteristics short-term post-procedure data non-rheumatic patients undergoing aortic, mitral or tricuspid ViV procedure. Results Single centre data-base analysis study, prospective collection, during period May 2015 September 2020. Among 106 included, 69 had etiology 37 were non-rheumatic. Rheumatic higher incidence female sex (73.9% vs 43.2%, respectively; p=0.004) atrial fibrillation (82.6% 45.9%, p<0.001). There no statistical difference regarding number previous surgeries (2 [3–1] 1 [2–1], p=0.103). tendency towards 30-day mortality (21.7% 5.4%, p=0.057) device success rate low, but similar between groups (78.3% 72.0%, p=0.710). Transapical access also group (92.6% 70.3%, p=0.008); Conclusion tend have when although not statistically significant. underwent greater than reported literature, high transapical procedure, contributed rate. Funding Acknowledgement Type funding sources: None.